Multiple Myeloma |
1 Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim;
2 Faculty of Technology, Sør Trøndelag University College, Trondheim;
3 Departments of Oncology;
4 Hematology;
5 Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, Norway
Correspondence: Randi Utne Holt, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N-7489 Trondheim, Norway. Phone: international +47.73550309. Fax: international +47.73598801. E-mail:randi.u.holt{at}ntnu.no
Multiple myeloma is characterized by the accumulation and dissemination of malignant plasma cells in the bone marrow. Cell migration is thought to be important for these events. We studied migration in a Transwell two-chamber assay and tested the motogenic effect of various cytokines. In addition to insulin-like growth factor-1 and stromal cell-derived growth factor-1
, previously known as chemoattractants for myeloma cells, we identified hepatocyte growth factor as a potent attractant for myeloma cells. Hepatocyte growth factor-mediated migration was dependent on phosphatidylinositol-3-kinase, involved the MAPK/Erk signaling cascade and VLA-4 integrins, but did not involve Akt, mTOR or G proteins.
Key words: myeloma, cell migration, hepatocyte growth factor, stromal cell-derived growth factor-1.
This article has been cited by other articles:
![]() |
A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma J. Biol. Chem., November 21, 2008; 283(47): 32628 - 32636. [Abstract] [Full Text] [PDF] |
||||